Inicio
→
Listar por autor

Listar por autor "Podzamczer Palter, Daniel"

Mostrando ítems 1-6 de 6

Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: a multicentre experience in antiretroviral therapy-naive and -experienced patients

Podzamczer Palter, Daniel; Imaz, A.; Pérez, I.; Viciana, P.; Valencia, E.; Curto, J.; Martín, T.; Castaño, M.; Rojas, J.; Espinosa, N.; Moreno, V.; Asensi, V.; Iribarren, José Antonio; Clotet, Bonaventura; Force, Lluis; Bachiller, P.; Knobel, Hernando; López Bernaldo de Quirós, Juan Carlos; Blanco, J.R.; Rozas N.; Vergas, J.; Ocampo, A.; Camacho, A.; Flores, J.; Gómez-Sirvent J.L. (Oxford University Press, 2014)

Objectives: To present clinical experience with a regimen including abacavir/lamivudine+darunavir/ritonavir in a cohort of HIV-1-infected patients. Methods: A retrospective, multicentre cohort study, including all ...
Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression

Di Yacovo, María Silvana; Moltó, José; Ferrer, Elena; Curran, Adrian; Else, Laura; Gisslén, Magnus; Clotet, Bonaventura; Tiraboschi, Juan M.; Niubò, Jordi; Vila, Antonia; Zetterberg, H.; Back, David; Podzamczer Palter, Daniel (Oxford University Press, 2015)

Objectives: The objective of this study was to assess whether a lower dose than the currently used one of darunavir/ ritonavir might achieve good CSF concentrations and contribute to inhibition of CNS viral replication. Patients ...
Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC

Santos, José R.; Saumoy, M.; Curran, Adrian; Bravo, Isabel; Navarro, Jordi; Estany, Carla; Podzamczer Palter, Daniel; Ribera, Esteban; Negredo, Eugenia; Clotet, Bonaventura; Paredes, Roger (International AIDS Society, 2014)

Abstract INTRODUCTION: Previous studies have described improvements on lipid parameters when switching from other antiretroviral drugs to tenofovir (TDF) and impairments in lipid profile when discontinuing TDF. [1-3] It ...
Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial

Moltó, José; Valle, Marta; Ferrer, Elena; Domingo, Pere; Curran, Adrian; Santos, José R.; Di Yacovo, María Silvana; Miranda, Cristina; Podzamczer Palter, Daniel; Clotet, Bonaventura (Oxford University Press, 2015)

Objectives: Maximizing ART efficiency is of growing interest. This study assessed the efficacy, safety, pharmacokinetics and economics of a darunavir dose-reduction strategy. Methods: This was a multicentre, randomized, ...
The Lipid-Lowering Effect of Tenofovir/ Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial

Santos, José R.; Saumoy, M.; Curran, Adrian; Bravo, Isabel; Llibre, Josep M.; Navarro, Jordi; Estany, Carla; Podzamczer Palter, Daniel; Ribera, Esteban; Negredo, Eugenia; Clotet, Bonaventura; Paredes, Roger (Oxford University Press, 2015)

Background. It is unknown if tenofovir disoproxil fumarate (TDF), which is often coformulated with the lipidneutral emtricitabine (FTC), has a lipid-lowering effect. Methods. We performed a randomized, crossover, ...
Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch

Tiraboschi, Juan M.; Muñoz-Moreno, José A.; Puertas, M.C.; Alonso-Villaverde, C.; Prats, A.; Ferrer, Elena; Rozas N.; Masó, Margarita; Ouchi, Dan; Martinez Picado, Francisco Javier; Podzamczer Palter, Daniel (Wiley, 2015)

Objectives: The aim of the study was to evaluate HIV-1 viral load (VL) and inflammatory markers in cerebrospinal fluid (CSF) and neurocognitive performance in patients with neurocognitive impairment (NCI) while they were ...

Mostrando ítems 1-6 de 6

Buscar en RIUVic

Listar

Todo DSpace

Listar por autor "Podzamczer Palter, Daniel"

Listar por autor "Podzamczer Palter, Daniel"

Buscar en RIUVic

Listar

Todo DSpace